It has not proved possible to respond to the hon. Member in the time available before Dissolution.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2019-11-05", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1167078/answer/previousversion/3767", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} } , "questionFirstAnswered" : [{"_value" : "2019-11-05T16:38:15.597Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-10-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "HIV Infection: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many local authorities do not have a PrEP impact trial site.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4073", "label" : {"_value" : "Biography information for Dr Sarah Wollaston"} } , "tablingMemberConstituency" : {"_value" : "Totnes"} , "tablingMemberPrinted" : [{"_value" : "Dr Sarah Wollaston"} ], "uin" : "7134"} , {"_about" : "http://data.parliament.uk/resources/1167079", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1167079/answer", "answerText" : {"_value" : "
It has not proved possible to respond to the hon. Member in the time available before Dissolution.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2019-11-05", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1167079/answer/previousversion/3763", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} } , "questionFirstAnswered" : [{"_value" : "2019-11-05T16:42:23.103Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-10-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "HIV Infection: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to support local authorities that do not have a PrEP impact trial prepare for routine commissioning.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4073", "label" : {"_value" : "Biography information for Dr Sarah Wollaston"} } , "tablingMemberConstituency" : {"_value" : "Totnes"} , "tablingMemberPrinted" : [{"_value" : "Dr Sarah Wollaston"} ], "uin" : "7135"} , {"_about" : "http://data.parliament.uk/resources/1167081", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1167081/answer", "answerText" : {"_value" : "
It has not proved possible to respond to the hon. Member in the time available before Dissolution.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2019-11-05", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1167081/answer/previousversion/3771", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} } , "questionFirstAnswered" : [{"_value" : "2019-11-05T16:39:46.243Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-10-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "HIV Infection: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that sufficient places are available in each clinic for the duration of the PreP trial.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4073", "label" : {"_value" : "Biography information for Dr Sarah Wollaston"} } , "tablingMemberConstituency" : {"_value" : "Totnes"} , "tablingMemberPrinted" : [{"_value" : "Dr Sarah Wollaston"} ], "uin" : "7136"} , {"_about" : "http://data.parliament.uk/resources/1148172", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1148172/answer", "answerText" : {"_value" : "
The Department is doing everything appropriate to prepare for leaving the European Union. We want to reassure patients that our plans should ensure the uninterrupted supply of medicines and medical products once we have left the EU.<\/p>
The Department, as part of our EU exit preparations, is implementing a multi-layered approach to mitigate potential disruption to supply, which consists of stockpiling where possible, securing freight capacity, changing or clarifying regulatory requirements, procuring additional warehousing, working closely with industry to improve trader readiness and putting in place the National Supply Disruption Response to manage potential shortages. Further details can be found at the following link:<\/p>
<\/p>
https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans<\/a><\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
}
, "answeringMemberConstituency" : {"_value" : "Charnwood"}
, "answeringMemberPrinted" : {"_value" : "Edward Argar"}
, "dateOfAnswer" : {"_value" : "2019-10-08", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-10-08T13:51:02.857Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-10-03", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the availability of medicines in the event that the UK leaves the EU without a deal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4073", "label" : {"_value" : "Biography information for Dr Sarah Wollaston"}
}
, "tablingMemberConstituency" : {"_value" : "Totnes"}
, "tablingMemberPrinted" : [{"_value" : "Dr Sarah Wollaston"}
], "uin" : "294144"}
, {"_about" : "http://data.parliament.uk/resources/1148176", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1148176/answer", "answerText" : {"_value" : " Operation Yellowhammer is a cross-Government programme of work to ensure that the United Kingdom is prepared to deal with the potential reasonable worst-case scenario impacts of leaving the European Union without a deal.<\/p> <\/p> On 11 September, the Government published planning assumptions for exiting the European Union without a deal at the following link:<\/p>